This content is machine translated New approvals, current study data and ADC development Antibody-drug conjugates in gynecologic oncology Antibody-drug conjugates (ADCs) have profoundly changed gynecological oncology in a very short space of time. Within just two years, three ADCs – mirvetuximab soravtansine, tisotumab vedotin and trastuzumab deruxtecan –...…
